Drug Profile
Senrebotase - AbbVie/Ipsen
Alternative Names: AGN-214868; SXN 100323; TEMLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Health Protection Agency Porton Down
- Developer Allergan
- Class Bacterial toxins; Endopeptidases; Non-opioid analgesics; Recombinant proteins; Urologics
- Mechanism of Action SNARE protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder; Postherpetic neuralgia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 27 Aug 2019 Discontinued - Phase-II for Overactive bladder in USA, France, Netherlands (Intravesicular)
- 27 Aug 2019 Discontinued - Phase-II for Postherpetic neuralgia in USA, Germany, Poland, Austria, Czech Republic (Intradermal)